- Home
- HUHU vs GNLX Comparison
HUHU vs GNLX Comparison
Compare HUHU & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUHU
- GNLX
- Stock Information
- Founded
- HUHU 2015
- GNLX 2001
- Country
- HUHU China
- GNLX United States
- Employees
- HUHU N/A
- GNLX N/A
- Industry
- HUHU
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- HUHU
- GNLX Health Care
- Exchange
- HUHU NYSE
- GNLX Nasdaq
- Market Cap
- HUHU 106.3M
- GNLX 112.5M
- IPO Year
- HUHU 2024
- GNLX 2023
- Fundamental
- Price
- HUHU $7.35
- GNLX $3.44
- Analyst Decision
- HUHU
- GNLX Strong Buy
- Analyst Count
- HUHU 0
- GNLX 4
- Target Price
- HUHU N/A
- GNLX $17.75
- AVG Volume (30 Days)
- HUHU 49.3K
- GNLX 152.2K
- Earning Date
- HUHU 02-22-2025
- GNLX 08-13-2025
- Dividend Yield
- HUHU N/A
- GNLX N/A
- EPS Growth
- HUHU N/A
- GNLX N/A
- EPS
- HUHU N/A
- GNLX N/A
- Revenue
- HUHU $18,149,244.00
- GNLX N/A
- Revenue This Year
- HUHU N/A
- GNLX N/A
- Revenue Next Year
- HUHU N/A
- GNLX N/A
- P/E Ratio
- HUHU N/A
- GNLX N/A
- Revenue Growth
- HUHU 8.47
- GNLX N/A
- 52 Week Low
- HUHU $2.95
- GNLX $1.60
- 52 Week High
- HUHU $9.89
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- HUHU N/A
- GNLX 65.71
- Support Level
- HUHU N/A
- GNLX $2.80
- Resistance Level
- HUHU N/A
- GNLX $3.61
- Average True Range (ATR)
- HUHU 0.00
- GNLX 0.22
- MACD
- HUHU 0.00
- GNLX 0.05
- Stochastic Oscillator
- HUHU 0.00
- GNLX 80.23
About HUHU HUHUTECH INTL GROUP INC
HUHUTECH International Group Inc specializes in providing factory facility management and monitoring systems, including high-purity gas, chemicals and liquid system and factory management and control systems for industrial clients, who are mainly semi-conductor manufacturers and electronics manufacturers in China. The products and services are widely used by semi-conductor manufacturers, LED and micro-electronics factories, as well as some pharmaceutical, food and beverage manufacturers.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.